FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide

FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide

The U.S. Food and Drug Administration has taken a significant regulatory step by proposing a ban on the bulk compounding of two widely used glucagon-like peptide 1 (GLP-1) receptor agonists: semaglutide and tirzepatide. The move targets compounding pharmacies that produce large quantities of these drugs outside the traditional pharmaceutical supply chain, a practice that has grown rapidly amid soaring demand for obesity and diabetes treatments.

Details of the FDA Proposal

The FDA’s proposal explicitly names both semaglutide and tirzepatide, seeking to prohibit their bulk compounding at pharmacies operating under Section 503B of the Federal Food, Drug, and Cosmetic Act. This section allows outsourcing facilities to compound drugs from bulk drug substances, provided those substances are on a specific list known as the “bulks list.” Adding semaglutide and tirzepatide to a separate list of substances that cannot be used in bulk compounding would effectively end the practice for these two drugs.

The proposal covers both the active pharmaceutical ingredients and any finished dosage forms compounded from them. If finalized, pharmacies would no longer be permitted to produce large batches of semaglutide or tirzepatide for distribution to clinics, hospitals, or patients without a patient-specific prescription. The FDA has not yet issued a final rule, but the announcement signals a tightening of oversight that could reshape the market for compounded weight loss and diabetes medications.

Drugs Named in the Ban

Semaglutide, marketed under brand names such as Ozempic and Wegovy, is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, slows gastric emptying, and reduces appetite. Tirzepatide, sold as Mounjaro and Zepbound, is a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Its mechanism provides additional metabolic benefits, and it has demonstrated superior weight loss outcomes in clinical trials.

Both drugs have faced intermittent shortages since late 2022, driven by unprecedented demand. During shortage periods, the FDA has historically permitted compounding pharmacies to produce “essentially a copy” of the commercially available product, a practice allowed under the Drug Shortage Relief Act. However, the agency now appears to be signaling that the shortage situation has stabilized enough to restrict compounding, or that the risks of unapproved bulk compounding outweigh the benefits.

Focus on Bulk Compounding

Bulk compounding refers to the practice of preparing drug products from large quantities of active pharmaceutical ingredients (APIs) rather than from finished dosage forms. This is distinct from patient-specific compounding, where a pharmacy makes a customized dose for an individual prescription. Under Section 503B, outsourcing facilities can compound without a patient-specific prescription, provided they comply with current good manufacturing practices and report adverse events.

The FDA’s concern with bulk compounding of semaglutide and tirzepatide centers on safety and quality control. The drugs are peptides, which require precise manufacturing conditions to maintain stability and potency. Compounded versions have been found to contain impurities, incorrect concentrations, or salt forms not present in the FDA-approved products. In some cases, patients have reported adverse events after using compounded semaglutide, including gastrointestinal distress and injection site reactions that differ from the branded product’s profile.

Furthermore, the FDA has noted that compounding facilities may use unapproved salts of these peptides. For example, semaglutide base and semaglutide acetate are chemically distinct from the FDA-approved semaglutide sodium salt. The agency has issued warning letters to several compounding pharmacies for marketing such unauthorized versions. The proposal would remove any ambiguity by explicitly prohibiting the use of semaglutide and tirzepatide as bulk drug substances.

Scientific and Regulatory Context

Peptide therapies like semaglutide and tirzepatide represent a class of biologics that require stringent quality control. Their molecular weight, amino acid sequence, and three-dimensional structure are critical to their function. Bulk compounding introduces risks because these peptides degrade easily when exposed to heat, light, or pH changes. Outsourcing facilities may not have the specialized equipment needed to validate stability over the product’s shelf life.

Dr. Sarah L. Johnson, a pharmaceutical policy expert, commented on the proposal: “The FDA is walking a tightrope between ensuring patient access during shortages and protecting public health from unregulated products. Banning bulk compounding of these two drugs indicates that the agency believes the shortage risk is now lower than the safety risk.” Her assessment highlights the regulatory balancing act that underpins the proposal.

This is not the first time the FDA has targeted specific drugs for restricted compounding. In 2021, the agency proposed placing several hormones on the same restricted list, citing similar concerns about quality and safety. The current proposal follows a pattern of increased enforcement in the compounding sector since the 2012 fungal meningitis outbreak linked to a compounding pharmacy, which resulted in hundreds of fatalities and led to the Drug Quality and Security Act.

Implications for Researchers and Health-Conscious Consumers

For researchers studying GLP-1 receptor agonists, the ban could limit access to raw materials for laboratory studies. Bulk compounds are often used in preclinical work and analytical testing. However, the FDA’s action does not affect pure research-grade peptides purchased from chemical suppliers for in vitro or animal studies, as long as those substances are not intended for human use.

Health-conscious consumers who rely on compounded semaglutide or tirzepatide for weight loss due to cost or insurance barriers may face challenges. Compounded versions are typically cheaper than brand-name drugs, and many patients turn to them during shortages. If the ban takes effect, those without coverage for the branded products may need to explore therapeutic alternatives or address underlying issues with diet and exercise under medical supervision.

It is also worth noting that compounding is not the only avenue for affordable access. Patient assistance programs, generic alternatives (once patents expire), and insurance formulary negotiations can influence out-of-pocket costs. The FDA’s proposal does not address these systemic issues, but it removes a source of unregulated supply.

Frequently Asked Questions

Q: Why is the FDA proposing a ban on bulk compounding of semaglutide and tirzepatide?

A: The FDA is concerned about safety and quality control in compounded versions of these drugs. Bulk compounding can lead to impurities, incorrect dosing, and the use of unapproved salt forms, which pose risks to patients. The agency also wants to ensure that patients receive FDA-approved products whenever possible.

Q: Will this ban affect patient-specific compounding for individual prescriptions?

A: The proposal specifically targets bulk compounding under Section 503B, where outsourcing facilities produce large batches without patient-specific prescriptions. Traditional compounding for an individual patient’s prescription, based on a valid medical need, may still be permitted if the drug is on the FDA’s shortage list or meets other criteria. However, the proposal narrows the circumstances under which compounding is allowed.

Q: When would the ban take effect, and can the public comment on it?

A: The FDA has issued a proposed rule, which is open for public comment typically for 60 to 90 days. After reviewing comments, the agency may finalize, modify, or withdraw the proposal. The timeline for finalization is uncertain but could be several months to a year.

Q: Are there any alternatives for patients who cannot afford or access brand-name semaglutide or tirzepatide?

A: Patients should consult their healthcare provider about manufacturer patient assistance programs, insurance coverage options, or therapeutic alternatives such as older GLP-1 agonists like liraglutide, lifestyle interventions, or bariatric surgery. Compounded versions carry risks and should be used only under the guidance of a licensed prescriber reading all safety warnings.